By David Tuller, DrPH If the results for a trial’s primary outcome do not meet the threshold for what is considered a “clinically significant” benefit, it goes without saying—or at least it should--that investigators have no legitimate grounds for promoting their intervention as “effective.” This is especially true when the ...

By David Tuller, DrPH I have written frequently about Cochrane, the organization renowned for its systematic reviews of medical interventions, and its deeply flawed review of exercise therapies for ME/CFS--including its decision last month to abandon its commitment to produce a new version. Now Hilda Bastian, an Australia health consumer ...

By David Tuller, DrPH In November, 2023, journalists Betsy Ladyzhets and Miles Griffis launched The Sick Times, a publication devoted to, per its tagline, “chronicling the Long Covid crisis.” Both of them had been covering the pandemic, and Griffis had written of his own Long Covid experience. The Sick Times ...

By David Tuller, DrPH Last February, The BMJ published a paper called “Clinical effectiveness of an online supervised group physical and mental health rehabilitation programme for adults with post-covid-19 condition (REGAIN study): multicentre randomised controlled trial,” from McGregor et al. The study purported to have proven that this multi-disciplinary intervention ...

By David Tuller, DrPH In October, I spent 10 days traveling around Ireland and giving a talk called "Bad Science, Bad Medicine: How Flawed Biopsychosocial Studies on ME, Long Covid, etc Harm Patients." (I wrote about the trip here.) I came as a guest of the Irish ME/CFS Association, which ...